Atypical haemolytic uraemic syndrome (aHUS) is a rare and complex blood disorder that requires specialized treatment approaches to protect the kidneys and other organs from serious damage. Modern treatment strategies focus on controlling the overactive immune response that causes blood clots, managing symptoms, and preventing disease recurrence.

Understanding Treatment Goals for aHUS

The treatment of atypical haemolytic uraemic syndrome centers on several key objectives that work together to improve patient outcomes and quality of life. The primary aim is to stop the uncontrolled activation of the complement system, which is the part of the immune system that mistakenly attacks the cells lining blood vessels in people with this condition. When the complement system becomes overactive, it triggers the formation of tiny blood clots throughout the body, particularly in the kidneys, which can lead to organ damage and potentially life-threatening complications.^[1]

Treatment strategies must address the immediate crisis when someone experiences an acute episode, but they also need to consider long-term management to prevent future episodes. Since aHUS often results from genetic mutations that affect how the body regulates its immune response, many patients require ongoing therapy rather than a short course of treatment. The specific approach varies depending on whether the condition is caused by inherited genetic changes, acquired antibodies against complement proteins, or other underlying factors.^[3]

Healthcare providers also focus on managing the three hallmark features that typically appear together in aHUS: microangiopathic hemolytic anemia (where red blood cells break down faster than the body can replace them), thrombocytopenia (a shortage of platelets that help blood clot normally), and acute kidney injury. Each of these conditions requires careful monitoring and supportive care to prevent permanent organ damage. The treatment plan must be individualized based on disease severity, genetic findings, patient age, and whether certain triggers like pregnancy, infection, or medications are involved.^[1]

Standard Treatment Approaches

Before the development of targeted therapies, the standard approach to treating atypical haemolytic uraemic syndrome relied heavily on plasma therapy, which includes both plasma exchange (also called plasmapheresis) and plasma infusion. Plasma exchange involves removing the patient’s blood plasma and replacing it with fresh frozen plasma from healthy donors. This process serves two purposes: it removes potentially harmful antibodies or abnormal complement proteins from circulation, and it provides healthy complement regulatory proteins that the patient’s body may be lacking.^[9]

During plasma exchange, blood is withdrawn from the patient and passed through a specialized machine that separates plasma from blood cells. The patient’s plasma, which may contain the factors causing the disease, is discarded, and the blood cells are mixed with donor plasma before being returned to the patient’s body. This procedure is typically performed daily or several times per week during acute episodes and must be continued until laboratory tests show improvement in platelet counts, red blood cell counts, and kidney function markers.^[11]

Plasma infusion is a simpler alternative where fresh frozen plasma is given directly through a vein without removing the patient’s own plasma. This approach is sometimes used when patients cannot tolerate the more intensive plasma exchange procedure or when the volume of plasma that needs to be replaced is manageable. However, plasma infusion has limitations because it does not remove harmful substances already circulating in the blood, and some patients may develop fluid overload, especially if they already have kidney problems.^[11]

The effectiveness of plasma therapy varies considerably depending on the underlying genetic defect. Patients with certain mutations respond better than others, and some individuals require plasma therapy for extended periods or even indefinitely to prevent disease recurrence. Treatment must begin as quickly as possible after diagnosis, ideally within 24 hours of symptom onset, to maximize the chances of kidney recovery and prevent permanent damage.^[11]

Supportive care forms another crucial component of standard treatment. During acute episodes, patients often need hospitalization to receive intravenous fluids and electrolytes, which help maintain proper fluid balance and correct mineral imbalances caused by kidney dysfunction. Careful monitoring of blood pressure is essential, as many patients develop hypertension (high blood pressure) that requires medication to control. Uncontrolled high blood pressure can worsen kidney damage and increase the risk of complications affecting the heart and brain.^[1]

When kidney function becomes severely impaired, patients may require dialysis, a procedure that artificially filters waste products and excess fluid from the blood. Dialysis can be temporary while waiting for kidney function to recover, or it may become necessary on a long-term basis if permanent kidney damage has occurred. There are two main types of dialysis: hemodialysis, where blood is filtered through an external machine, and peritoneal dialysis, where the lining of the abdomen is used as a natural filter.^[11]

Blood transfusions are frequently needed to treat the severe anemia that develops when red blood cells are rapidly destroyed. Fresh red blood cells provided through transfusion help restore the blood’s oxygen-carrying capacity and relieve symptoms like extreme fatigue, shortness of breath, and rapid heartbeat. In some cases, platelet transfusions may be considered, although this is controversial because adding more platelets could theoretically worsen clot formation in small blood vessels.^[12]

For patients who develop end-stage renal disease (complete kidney failure) despite treatment, kidney transplantation may eventually be considered. However, this presents a unique challenge because the same genetic defects or antibodies that caused the original kidney damage can attack the transplanted kidney. The risk of disease recurrence in the transplanted kidney varies from 10 to over 50 percent depending on the specific genetic mutation involved, making careful patient selection and ongoing monitoring critical.^[3]

Breakthrough Treatment in Clinical Trials and Modern Practice

A revolutionary advance in treating atypical haemolytic uraemic syndrome came with the development of complement inhibitors, medications specifically designed to block the overactive complement system. The first such drug approved for aHUS was eculizumab (marketed as Soliris), a monoclonal antibody that targets a specific protein in the complement cascade called C5. By binding to C5, eculizumab prevents it from being split into its active components C5a and C5b-9, which are responsible for inflammation and cell destruction. This effectively shuts down the harmful end stage of complement activation while leaving earlier parts of the immune response intact.^[9]

Eculizumab was tested in multiple clinical trials that demonstrated remarkable effectiveness. In these studies, patients who had been dependent on regular plasma exchange were able to stop that treatment once they began receiving eculizumab. The drug was given as an intravenous infusion initially every week for the first month, then every two weeks for ongoing maintenance. Results showed improvements in platelet counts, reduced destruction of red blood cells, and significant recovery of kidney function in many patients. Some individuals who had been on dialysis were able to discontinue it after starting eculizumab therapy.^[9]

The clinical trial data also revealed that eculizumab could prevent disease recurrence in patients receiving kidney transplants, a major breakthrough since recurrence had been a significant barrier to successful transplantation in aHUS patients. When started before or immediately after transplant surgery and continued long-term, eculizumab dramatically reduced the risk of the new kidney being damaged by the same complement-mediated process that destroyed the original kidneys.^[9]

Following the success of eculizumab, a second complement inhibitor called ravulizumab (marketed as Ultomiris) was developed and approved by regulatory authorities including the U.S. Food and Drug Administration. Ravulizumab works through the same mechanism as eculizumab by blocking C5, but it has a longer duration of action in the body. This means patients can receive infusions less frequently—every eight weeks instead of every two weeks—which significantly improves convenience and quality of life while maintaining the same therapeutic effect.^[12][18]

Both eculizumab and ravulizumab have been studied in various clinical trial phases. Phase I trials focused on establishing safety and determining appropriate dosing in small groups of healthy volunteers and patients. Phase II trials expanded to larger patient groups to evaluate how well the drugs worked in controlling disease activity and improving clinical outcomes like kidney function and blood counts. Phase III trials compared the new treatments against existing standard therapies, particularly plasma exchange, and confirmed superior outcomes with the complement inhibitors.^[13]

The mechanism of action for these drugs is highly specific. Under normal circumstances, the complement system acts as a critical defense against infections by marking foreign invaders for destruction. However, in aHUS, genetic mutations or antibodies cause this system to mistakenly attack the body’s own cells, particularly the endothelial cells that line blood vessels. When complement proteins become activated, they form what is called a membrane attack complex (C5b-9) that literally punches holes in cell membranes, killing the cells. By preventing C5 from being cleaved into C5a and C5b, eculizumab and ravulizumab stop the formation of this destructive complex while preserving the earlier, protective functions of complement.^[9]

Clinical trial results have been very encouraging across different patient populations. Studies included both children and adults, as well as patients who were newly diagnosed and those who had been struggling with the disease for years. Many participants experienced what researchers call “complete thrombotic microangiopathy response,” meaning their platelet counts normalized, red blood cell destruction stopped, and kidney function improved to near-normal levels. Even patients who entered the trials already on dialysis had a reasonable chance of kidney function recovery allowing them to stop dialysis.^[9]

The safety profile of these complement inhibitors has been generally favorable in clinical trials, with most side effects being mild to moderate. Common side effects include headache, nausea, and fatigue. However, there is one serious risk that requires special attention: because these drugs block part of the complement system, they significantly increase susceptibility to infections caused by certain bacteria, particularly Neisseria meningitidis, which causes meningococcal disease (meningitis and bloodstream infections).^[12]

Clinical trials have been conducted in multiple countries including the United States, various European nations, and other regions worldwide. Eligibility for these trials typically required confirmed diagnosis of aHUS based on laboratory evidence of complement-mediated thrombotic microangiopathy and exclusion of other causes of similar symptoms. Some trials specifically enrolled patients who had genetic mutations identified, while others included patients regardless of whether a specific genetic cause was found, since roughly half of aHUS cases do not have an identifiable mutation with current testing methods.^[3]

Ongoing research continues to explore additional complement inhibitors and alternative approaches to blocking the harmful complement activation. Scientists are investigating drugs that target different points in the complement cascade, potentially offering more options for patients who might not respond optimally to C5 inhibitors. Some experimental therapies in earlier phases of clinical development aim to provide longer-lasting complement control or even gene therapy approaches to correct the underlying genetic defects.^[13]

The duration of treatment with complement inhibitors remains a topic of ongoing study. Current evidence suggests that most patients require long-term, potentially lifelong treatment because stopping the medication often leads to disease recurrence within weeks or months. However, researchers are carefully studying whether some patients might be able to safely discontinue treatment after an extended period of disease control, particularly if their kidneys have fully recovered and they have not experienced any triggering events.^[9]

Most common treatment methods

• Complement inhibitor therapy
  • Eculizumab (Soliris) administered intravenously every two weeks after an initial loading period to block C5 protein and prevent complement-mediated cell damage
  • Ravulizumab (Ultomiris) given as intravenous infusion every eight weeks with the same mechanism as eculizumab but longer duration of action
  • Both drugs prevent formation of membrane attack complex by binding to C5 and stopping it from being cleaved into active components
  • Required vaccination against meningococcal bacteria before starting treatment due to increased infection risk
  • Generally continued long-term or lifelong to prevent disease recurrence
• Plasma therapy
  • Plasma exchange (plasmapheresis) where patient’s plasma is removed and replaced with fresh frozen plasma from donors
  • Removes harmful antibodies and abnormal complement proteins while providing healthy complement regulatory proteins
  • Typically performed daily or several times weekly during acute episodes
  • Plasma infusion as a simpler alternative where fresh frozen plasma is given intravenously without removing patient’s own plasma
  • Effectiveness varies depending on underlying genetic mutation
  • Must begin within 24 hours of symptom onset for best outcomes
• Supportive care
  • Intravenous fluids and electrolytes to maintain proper fluid balance and correct mineral imbalances
  • Blood pressure medications to control hypertension and prevent further kidney damage
  • Red blood cell transfusions to treat severe anemia caused by rapid cell destruction
  • Nutritional support including specialized diets to reduce burden on impaired kidneys
• Dialysis
  • Hemodialysis where blood is filtered through an external machine to remove waste products and excess fluid
  • Peritoneal dialysis using the abdominal lining as a natural filter
  • May be temporary while awaiting kidney recovery or long-term if permanent damage has occurred
  • Necessary when kidney function becomes severely impaired
• Kidney transplantation
  • Considered for patients who develop end-stage renal disease despite treatment
  • Risk of disease recurrence in transplanted kidney varies from 10 to over 50 percent depending on genetic mutation
  • Complement inhibitors may be used before and after transplant to prevent recurrence
  • Requires careful patient selection and ongoing monitoring

Managing Daily Life with aHUS

Living with atypical haemolytic uraemic syndrome requires ongoing attention to multiple aspects of health and wellbeing. Patients must maintain close communication with their healthcare team, which typically includes nephrologists (kidney specialists) and hematologists (blood disorder specialists) who have experience managing this rare condition. Regular monitoring through blood tests and other examinations is essential to detect any signs of disease activity before serious complications develop.^[14]

Medication adherence is absolutely critical for patients on complement inhibitor therapy. Missing doses or stopping treatment without medical supervision can trigger a rapid and severe disease recurrence. Patients need to understand their medication schedule, attend all infusion appointments, and report any unusual symptoms immediately. Keeping a record of laboratory results, treatments received, and how you feel can help both you and your doctors track disease patterns and adjust treatment as needed.^[14]

Diet and hydration play important supportive roles in managing kidney health. While specific dietary recommendations should come from your healthcare provider or a specialized kidney dietitian, general principles often include managing salt intake to control blood pressure and reduce fluid retention, and monitoring potassium and phosphorus levels if kidney function is impaired. Staying adequately hydrated is important, but patients with significant kidney damage may need to limit fluid intake to prevent overload.^[14]

Physical activity should be encouraged as tolerated. Regular, moderate exercise can improve overall health, energy levels, and emotional wellbeing. However, during acute episodes or when symptoms like severe fatigue are present, rest becomes more important. Finding the right balance requires listening to your body and communicating with your healthcare team about what level of activity is appropriate for your current condition.^[14]

The emotional and mental health impact of living with aHUS should not be underestimated. The unpredictable nature of the disease, fear of recurrence, and stress of managing a serious chronic condition can lead to anxiety, depression, and other mental health challenges. Research has shown that both patients and their family members experience significant emotional toll, including feelings of fear, guilt, and trauma that can persist long after the acute phase of illness. Seeking support from mental health professionals, joining patient support groups, or connecting with others who understand the experience can be tremendously helpful.^[17]

Patients need to be vigilant about avoiding potential triggers that could precipitate disease episodes. This includes prompt treatment of any infections, careful evaluation before taking new medications (as some drugs can trigger aHUS), and special precautions during pregnancy for women of childbearing age. Anyone with aHUS who becomes ill with an infection should seek medical attention promptly rather than waiting to see if symptoms resolve on their own.^[1]

Education about the condition empowers patients and families to be active participants in care. Understanding what aHUS is, how it affects the body, warning signs of potential problems, and when to seek emergency medical attention can improve outcomes. Patient organizations and foundations dedicated to aHUS provide valuable resources including educational materials, connections to specialists, and support networks that can make the journey less isolating.^[16]

Genetic counseling may be beneficial for patients and their families, particularly since aHUS often has a hereditary component. Family members of someone diagnosed with aHUS may want to undergo genetic testing to determine if they carry mutations that could put them at risk. Understanding the genetic aspects can help with family planning decisions and allow relatives who are carriers to be monitored or treated preventively if they experience potential triggers.^[16]

Carrying medical identification that explains your diagnosis can be life-saving in emergency situations. Many patient advocacy organizations provide emergency cards that briefly explain aHUS, list current medications, and provide contact information for your medical team. Having this information readily available helps emergency room doctors who may not be familiar with this rare condition provide appropriate care quickly.^[14]